Ingel Demedts

3.9k total citations
48 papers, 2.7k citations indexed

About

Ingel Demedts is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Physiology. According to data from OpenAlex, Ingel Demedts has authored 48 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Pulmonary and Respiratory Medicine, 18 papers in Oncology and 11 papers in Physiology. Recurrent topics in Ingel Demedts's work include Lung Cancer Treatments and Mutations (16 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers) and Lung Cancer Research Studies (10 papers). Ingel Demedts is often cited by papers focused on Lung Cancer Treatments and Mutations (16 papers), Chronic Obstructive Pulmonary Disease (COPD) Research (14 papers) and Lung Cancer Research Studies (10 papers). Ingel Demedts collaborates with scholars based in Belgium, United States and Spain. Ingel Demedts's co-authors include Guy Brusselle, Ken R. Bracke, Guy Joos, Karim Vermaelen, Tine Demoor, Romain Pauwels, Tania Maes, Jan P. van Meerbeeck, Geert M. Verleden and A. I. D'hulst and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Immunology and American Journal of Respiratory and Critical Care Medicine.

In The Last Decade

Ingel Demedts

48 papers receiving 2.7k citations

Peers

Countries citing papers authored by Ingel Demedts

Since Specialization

Citations

This map shows the geographic impact of Ingel Demedts's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ingel Demedts with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ingel Demedts more than expected).

Fields of papers citing papers by Ingel Demedts

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ingel Demedts. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ingel Demedts. The network helps show where Ingel Demedts may publish in the future.

Co-authorship network of co-authors of Ingel Demedts

This figure shows the co-authorship network connecting the top 25 collaborators of Ingel Demedts. A scholar is included among the top collaborators of Ingel Demedts based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ingel Demedts. Ingel Demedts is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	An acquired CCDC6:: RET gene fusion as resistance mechanism for Osimertinib in exon 21 EGFR(L858R) -mutated non-small cell lung cancer and its successful management with Osimertinib and Selpercatinib: a case report and review of literature 2025 ·Journal of Chemotherapy ·(unknown), (unknown), Ingel Demedts	1
2	Durvalumab in Combination With Olaparib Versus Durvalumab Alone as Maintenance Therapy in Metastatic NSCLC: The Phase 2 ORION Study 2023 ·Journal of Thoracic Oncology ·Myung‐Ju Ahn, Igor Bondarenko, Ewa Kalinka‐Warzocha, Byoung Chul Cho, Shunichi Sugawara, Gabriella Gálffy, Byoung Yong Shim, Nikolay Kislov, Rajnish Nagarkar, Ingel Demedts, Steven Gans, (unknown), Ross Stewart, Zhongwu Lai, Helen Mann, Xiaojin Shi, Maen Hussein	8
3	Indirect Costs Due to Lung Cancer-Related Premature Mortality in Four European Countries 2023 ·Advances in Therapy ·Goran Benčina, (unknown), Robert Hughes, (unknown), Carl A. Baxter, Stina Salomonsson, Ingel Demedts	10
4	A Randomized, Open-Label Phase II Study Evaluating Emibetuzumab Plus Erlotinib and Emibetuzumab Monotherapy in MET Immunohistochemistry Positive NSCLC Patients with Acquired Resistance to Erlotinib 2022 ·Clinical Lung Cancer ·D. Ross Camidge, Teresa Morán, Ingel Demedts, (unknown), Kathryn F. Mileham, Julian R. Molina, Óscar Juan, Gerold Bepler, Jonathan W. Goldman, Keunchil Park, Johan Wallin, Sameera R. Wijayawardana, Xuejing Aimee Wang, Volker Wacheck, Egbert F. Smit	19
5	Evaluation of the implementation of Value‐Based Healthcare with a weekly digital follow‐up of lung cancer patients in clinical practice 2022 ·European Journal of Cancer Care ·(unknown), Wim Marneffe, (unknown), Johan Hellings, Ingel Demedts	4
6	Real-World Treatment Patterns, Epidermal Growth Factor Receptor (EGFR) Testing and Outcomes in EGFR-Mutated Advanced Non-small Cell Lung Cancer Patients in Belgium: Results from the REVEAL Study 2021 ·Drugs - Real World Outcomes ·(unknown), Kristof Cuppens, (unknown), Ingel Demedts, Lore Decoster, Benoît Colinet, (unknown), Annelies Janssens, D. Galdermans, Thierry Pieters	8
7	1366TiP Tepotinib + osimertinib for EGFR-mutant NSCLC with resistance to first-line osimertinib due to MET amplification (METamp): INSIGHT 2 2021 ·Annals of Oncology ·Yi‐Long Wu, Christophe Dooms, Ernest Nadal, Jo Raskin, Ingel Demedts, Julien Mazières, Marie Wislez, (unknown), Lye Mun Tho, Chi‐Chuan Wang, Santiago Viteri, (unknown), Soon Hin How, (unknown), Masayuki Takeda, Rémi Veillon, Niki Karachaliou, Barbara Ellers‐Lenz, Egbert F. Smit	1
8	Diagnostic Performance of Chest CT for SARS-CoV-2 Infection in Individuals with or without COVID-19 Symptoms 2020 ·Radiology ·K. De Smet, Dieter De Smet, (unknown), (unknown), (unknown), (unknown), Ingel Demedts, Bernard Bouckaert, Stefaan Gryspeerdt, Geert A. Martens	68
9	135O A phase 1b study of necitumumab in combination with abemaciclib in patients with stage IV non-small cell lung cancer 2018 ·Journal of Thoracic Oncology ·Benjamin Besse, Fabrice Barlési, Ingel Demedts, José Fuentes Pradera, Aldo Renault, G. Robinet, Bente Frimodt‐Moller, (unknown), Johan Vansteenkiste	1
10	The Belgian trial with azithromycin for acute COPD exacerbations requiring hospitalization: an investigator-initiated study protocol for a multicenter, randomized, double-blind, placebo-controlled trial 2016 ·International Journal of COPD ·Kristina Vermeersch, (unknown), (unknown), Ingel Demedts, Hans Slabbynck, Joseph Aumann, Vincent Ninane, Geert M. Verleden, Thierry Troosters, Kris Bogaerts, Guy Brusselle, Wim Janssens	10
11	Azithromycin for prevention of exacerbations in severe asthma (AZISAST): a multicentre randomised double-blind placebo-controlled trial 2013 ·Thorax ·Guy Brusselle, (unknown), Paul Jordens, R DEMAN, Hans Slabbynck, (unknown), Geert M. Verleden, Ingel Demedts, Katia Verhamme, Anja Delporte, Bénédicte Demeyere, Geert Claeys, Jerina Boelens, Elizaveta Padalko, Johny Verschakelen, Georges Van Maele, Ellen Deschepper, Guy Joos	328
12	Selective accumulation of langerhans-type dendritic cells in small airways of patients with COPD 2010 ·Respiratory Research ·Geert R. Van Pottelberge, Ken R. Bracke, Ingel Demedts, (unknown), Susanne M. Reinartz, Cornelis M. van Drunen, Geert M. Verleden, Frank Vermassen, Guy Joos, Guy Brusselle	67
13	Dendritic Cells in Chronic Obstructive Pulmonary Disease 2008 ·American Journal of Respiratory and Critical Care Medicine ·Maria Tsoumakidou, Ingel Demedts, Guy Brusselle, Peter K. Jeffery	65
14	Accumulation of Dendritic Cells and Increased CCL20 Levels in the Airways of Patients with Chronic Obstructive Pulmonary Disease 2007 ·American Journal of Respiratory and Critical Care Medicine ·Ingel Demedts, Ken R. Bracke, (unknown), Dries Testelmans, Geert M. Verleden, Frank Vermassen, Guy Joos, Guy Brusselle	186
15	Dendritic Cell Maturity and Obstructive Airway Disease 2007 ·American Journal of Respiratory and Critical Care Medicine ·Ingel Demedts, Guy Joos, Guy Brusselle	3
16	Cigarette Smoke-Induced Pulmonary Inflammation and Emphysema Are Attenuated in CCR6-Deficient Mice 2006 ·The Journal of Immunology ·Ken R. Bracke, A. I. D'hulst, Tania Maes, Katrien Moerloose, Ingel Demedts, Serge Lebecque, Guy Joos, Guy Brusselle	196
17	Murine TLR4 Is Implicated in Cigarette Smoke-Induced Pulmonary Inflammation 2006 ·International Archives of Allergy and Immunology ·Tania Maes, Ken R. Bracke, Karim Vermaelen, Ingel Demedts, Guy Joos, Romain Pauwels, Guy Brusselle	78
18	Role of apoptosis in the pathogenesis of COPD and pulmonary emphysema 2006 ·Respiratory Research ·Ingel Demedts, Tine Demoor, Ken R. Bracke, Guy Joos, Guy Brusselle	413
19	Elevated MMP-12 protein levels in induced sputum from patients with COPD 2005 ·Thorax ·Ingel Demedts	191
20	Cigarette smoke-induced pulmonary emphysema in scid-mice. Is the acquired immune system required? 2005 ·Respiratory Research ·A. I. D'hulst, Tania Maes, Ken R. Bracke, Ingel Demedts, Kurt G. Tournoy, Guy Joos, Guy Brusselle	88

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact